In contrast, primary or innate resistance is very uncommon (7–9), suggesting that without the selective pressure of long-term pathway inhibition most melanoma cells with BRAF mutations are sensitive to RAF/MEK/ERK pathway inhibition. This evidence concerns the gene RAF1 and melanoma.